{"nctId":"NCT03668613","briefTitle":"Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis","startDateStruct":{"date":"2018-08-29","type":"ACTUAL"},"conditions":["Moderate to Severe Chronic Plaque-type Psoriasis"],"count":84,"armGroups":[{"label":"secukinumab low dose","type":"EXPERIMENTAL","interventionNames":["Drug: secukinumab low dose"]},{"label":"secukinumab high dose","type":"EXPERIMENTAL","interventionNames":["Drug: secukinumab high dose"]}],"interventions":[{"name":"secukinumab low dose","otherNames":["AIN457"]},{"name":"secukinumab high dose","otherNames":["AIN457"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Written informed assent and parental permission (age as per local law) obtained at screening before any assessment is performed.\n2. Must be 6 to less than 18 years of age at the time of randomization\n3. Moderate to Severe plaque psoriasis, defined as a PASI score ≥ 12, and IGA mod 2011 score of ≥ 3, and BSA involvement of ≥10%, at randomization.\n4. Subject being regarded by the investigator to be a candidate for systemic therapy.\n\nExclusion Criteria:\n\n1. Forms of psoriasis other than chronic plaque-type active at randomization\n2. Drug-induced psoriasis\n3. Ongoing use of prohibited treatments\n4. Female subjects of childbearing potential defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing and for 16 weeks after stopping study treatment\n5. Pregnant or nursing (lactating) females\n6. Subjects with total WBC count \\<2,500/μL, or platelets \\<100,000/μL or neutrophils \\<1,500/μL or hemoglobin \\<8.5 g/dL at screening\n7. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or the IL-17 receptor","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number and Percentage of Participants With PASI 75 Response","description":"Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \\& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section(head: 0.1, upper limbs: 0.2 body: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"PRIMARY","title":"Number and Percentage of Participants With IGA Mod 2011 0 or 1 Response","description":"Investigator will assess the disease using the validated Investigator Global Assessment (IGA) mod 2011 and rate the disease from a score of 0 (clear skin) to 4 (severe disease)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With PASI 90 Response","description":"Psoriasis Area and Severity Index (PASI) was assessed/calculated as per the standard procedure.\n\nPASI 90 represents the percentage (or number) of patients who have achieved a 90% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Secukinumab Concentration in Serum","description":"Mean (Standard Deviation) Secukinumab concentration levels in serum over time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":"33.0"},{"groupId":"OG001","value":"135","spread":"45.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":"10.9"},{"groupId":"OG001","value":"69.6","spread":"29.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","spread":"17.4"},{"groupId":"OG001","value":"91.2","spread":"34.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.9","spread":"15.5"},{"groupId":"OG001","value":"78.4","spread":"29.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6","spread":"12.4"},{"groupId":"OG001","value":"65.7","spread":"28.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":"11.2"},{"groupId":"OG001","value":"55.2","spread":"24.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":"10.8"},{"groupId":"OG001","value":"48.0","spread":"21.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":"9.01"},{"groupId":"OG001","value":"42.7","spread":"17.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":"10.8"},{"groupId":"OG001","value":"39.3","spread":"12.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":"8.68"},{"groupId":"OG001","value":"35.0","spread":"14.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"6.25"},{"groupId":"OG001","value":"38.8","spread":"17.2"}]}]}]},{"type":"SECONDARY","title":"Summary Table of Adverse Events","description":"An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study.\n\nTreatment emergent adverse events in this study are events that started after the first dose of study treatment and until 84 days after the last study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 84 days after the last study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":42},"commonTop":["COVID-19","Nasopharyngitis","Acne","Viral upper respiratory tract infection","Pyrexia"]}}}